12,372 trials
Postmenopausal Osteoporosis
Primary: Percentage Change From Baseline (%CfB) in Lumbar Spine Bone Mineral Density (BMD) — 5.68; 5.19 Percentage change from baseline
Kidney Stone · Pain, Postoperative · Addiction
Primary: Visual Analog Scale of Pain Score — 3.7; 2.0 units on a scale
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs — 85; 21 Participants
Bacterial Conjunctivitis
Primary: Number of Subjects With Clinical Resolution of Bacterial Conjunctivitis — 71; 59 Participants — p=0.2219
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology (ACR) 50 Response at Week 16 — 10.0; 43.9; 45.7 percentage of participants — p=<0.001
Dry Eye Disease (DED)
Primary: Change From Baseline (CFB) in Total Corneal Fluorescein Staining (tCFS) at Day 57 — -2.0; -1.0 units on a scale
Smallpox
Primary: Cmin — 792 ng/mL
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
Stage III Distal Bile Duct Cancer AJCC v8 · Stage III Gallbladder Cancer AJCC v8 · Stage III Intrahepatic Cholangiocarcinoma AJCC v8
Primary: Overall Survival (OS) — 14.0; 13.6 months — p=0.41
Spinal Muscular Atrophy
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 13; 24; 65; 12 Participants
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment — 5.5; 4.0 months — p=0.0001
Short Bowel Syndrome
Primary: Change in Weekly Parenteral Support (PS) Volume — -5.13; -3.76; -2.85 L/week — p=0.0039
Glabellar Frown Lines
Primary: Number of Responders Using the Global Aesthetic Improvement Scale (GAIS) at Month 1 — 92; 3 Participants — p=<0.001
Endometrial Neoplasms
Primary: Progression-free Survival (PFS) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)…
Head and Neck Squamous Cell Carcinoma
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) — 39.3…